The Effect of Erector Spinae Plane Block in Herpes Zoster Patients Who Are Ineffective with Conventional Treatment

Not Applicable

Not yet recruiting

• Conditions: Pain management; Herpes zoster; Postherpetic neuralgia; Infection - Other infectious diseases; Inflammatory and Immune System - Normal development and function of the immune system; Anaesthesiology - Pain management

• Registration Number: ACTRN12624001149550
• Lead Sponsor: Necmettin Erbakan University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-09-23
• Last Update Posted: 30 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Volunteers aged between 18 and 80 years, who have passed the acute phase of the disease, whose vesicles have dried, whose antiviral treatment has been completed, who have involvement of thoracic region dermatomes, who have a DN4 score over 4, who have not started neuropathic pain treatment, and who have been diagnosed with herpes zoster whose pain has not become chronic will be included in the study.

Exclusion Criteria

Patients with diabetes mellitus, another disease that may cause neuropathic pain, malignancy, previous treatment for neuropathic pain, bacterial infection in the affected dermatome, autoimmune disease, drug and alcohol addiction, smoking, chronic renal failure and liver failure, immunodeficiency, those who do not agree to participate in the study, and those who are pregnant or breastfeeding will be excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in CD3 levels [CD3 levels will be studied in the blood samples taken. First visit<br>1 day after the block is applied (intervention group) or at the first check-up where it is determined that the patients in the control group have responded to pregabalin treatment and the dose is fixed (control group)<br>At the end of the 3rd month post-baseline];Rate of development of postherpetic neuralgia[Numeric Rating Scale Score At the end of the 3 months];Change in CD4 levels [CD4 levels will be studied in the blood samples taken. First visit<br>1 day after the block is applied (intervention group) or at the first check-up where it is determined that the patients in the control group have responded to pregabalin treatment and the dose is fixed (control group)<br>At the end of the 3rd month post-baseline]